



TRAINING QUIZ

1. Which of the following is not true?

- a. YCANTH is a drug-device combination product.
- b. The active ingredient in YCANTH is cantharidin topical solution 0.7%.
- c. YCANTH is approved for multi-use application to molluscum lesions and can be used for separate patient visits or for different patients.
- d. YCANTH contains a bittering agent, denatonium benzoate, to help mitigate the risk of accidental ingestion.

2. True or False?

Only a licensed, trained, Healthcare provider can administer YCANTH to patients 2 years of age and older for the treatment of Molluscum contagiosum.

3. Which of the following statements is true?

- a. YCANTH should be stored at controlled room temperature.
- b. YCANTH should be refrigerated.

4. Which of the following statements is true?

- a. Healthcare professionals should remove the YCANTH cap **after** the YCANTH applicator is activated in the YCANTH break tool.
- b. Healthcare professionals should remove the YCANTH cap **before** the YCANTH applicator is activated in the YCANTH break tool.

5. What type of finger pressure should be applied to the YCANTH applicator to expel a small droplet onto a molluscum lesion?

- a. Heavy pressure to help ensure a small droplet of YCANTH is applied to the molluscum lesion and healthy, unaffected skin.
- b. Gentle pressure to help ensure a small droplet of YCANTH is applied only to the molluscum lesion and keep YCANTH off healthy, unaffected skin.

6. How long does it take for YCANTH solution to completely dry after applying a small droplet onto a molluscum lesion?

- a. Up to 5 minutes, but it is okay to dismiss a patient before the YCANTH solution dries because it cannot ever spread, even before drying.
- b. Up to 5 minutes and never dismiss a patient before the YCANTH solution dries because it can spread to unaffected, healthy skin causing unintended blisters and possible adverse events.



TRAINING QUIZ

7. True or False?

The healthcare professional should cover treated molluscum lesions with bandages, so the lesions are not visible.

8. Which of the following is true?

- Ocular toxicity can occur if YCANTH comes in contact with the eyes.
- Adverse reactions from contact of YCANTH with the eyes can include corneal necrosis, ocular perforation, and deep ocular injuries.
- Do not apply YCANTH near or to the eyes or mucosal surfaces.
- If YCANTH comes in contact with the eyes, flush eyes with water for at least 15 minutes and seek medical attention immediately.
- All of the above

9. Which of the following statements about YCANTH is true?

- A. Most common (incidence $\geq 1\%$) adverse reactions are local skin reactions at the application site such as vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion.
- Wash lesions that are treated with YCANTH with soap and water approximately 24 hours after treatment. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to 24 hours after treatment and report the Adverse Event.
To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-837-7422 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Local skin reactions are expected and should be reported if they are severe.
- The solvents in YCANTH can be flammable and should not be used near an open flame.
- All of the above are true.

10. All the following are part of the YCANTH Instructions for Use, except:

- Wear gloves and eye protection when administering YCANTH.
- If the YCANTH applicator does not work properly, it is acceptable to modify the tip of the applicator if needed.
- Only apply topically as a single application to cover each lesion.
- Administer no more than two YCANTH applicators during a single treatment session, every 3 weeks as needed.
- Inspect the YCANTH applicator for damage such as broken glass ampules, cut or cracked tubes. If there is damage, this should be reported within 24 hours to Verrica Pharmaceuticals Inc. at 1-877-837-7422 (1-877-Verrica).



TRAINING QUIZ ANSWER SHEET

ANSWERS ARE IN **BLUE**

1. Which of the following is not true?

- a. YCANTH is a drug-device combination product.
- b. The active ingredient in YCANTH is cantharidin topical solution 0.7%.
- c. **YCANTH is approved for multi-use application to molluscum lesions and can be used for separate patient visits or for different patients.**
- d. YCANTH contains a bittering agent, denatonium benzoate, to help mitigate the risk of accidental ingestion.

2. True or False?

Only a licensed, trained, Healthcare provider can administer YCANTH to patients 2 years of age and older for the treatment of Molluscum contagiosum.

TRUE

3. Which of the following statements is true?

- a. **YCANTH should be stored at controlled room temperature.**
- b. YCANTH should be refrigerated.

4. Which of the following statements is true?

- a. **Healthcare professionals should remove the YCANTH cap after the YCANTH applicator is activated in the YCANTH break tool.**
- b. Healthcare professionals should remove the YCANTH cap **before** the YCANTH applicator is activated in the YCANTH break tool.

5. What type of finger pressure should be applied to the YCANTH applicator to expel a small droplet onto a molluscum lesion?

- a. Heavy pressure to help ensure a small droplet of YCANTH is applied to the molluscum lesion and healthy, unaffected skin.
- b. **Gentle pressure to help ensure a small droplet of YCANTH is applied only to the molluscum lesion and keep YCANTH off healthy, unaffected skin.**

6. How long does it take for YCANTH solution to completely dry after applying a small droplet onto a molluscum lesion?

- a. Up to 5 minutes, but it is okay to dismiss a patient before the YCANTH solution dries because it cannot ever spread, even before drying.
- b. **Up to 5 minutes and never dismiss a patient before the YCANTH solution dries because it can spread to unaffected, healthy skin causing unintended blisters and possible adverse events.**



TRAINING QUIZ ANSWER SHEET

ANSWERS ARE IN **BLUE**

7. True or False?

The healthcare professional should cover treated molluscum lesions with bandages, so the lesions are not visible.

FALSE

8. Which of the following is true?

- a. Ocular toxicity can occur if YCANTH comes in contact with the eyes.
- b. Adverse reactions from contact of YCANTH with the eyes can include corneal necrosis, ocular perforation, and deep ocular injuries.
- c. Do not apply YCANTH near or to the eyes or mucosal surfaces.
- d. If YCANTH comes in contact with the eyes, flush eyes with water for at least 15 minutes and seek medical attention immediately.
- e. **All of the above**

9. Which of the following statements about YCANTH is true?

- a. A. Most common (incidence $\geq 1\%$) adverse reactions are local skin reactions at the application site such as vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion.
- b. Wash lesions that are treated with YCANTH with soap and water approximately 24 hours after treatment. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to 24 hours after treatment and report the Adverse Event.
To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-837-7422 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Local skin reactions are expected and should be reported if they are severe.
- c. The solvents in YCANTH can be flammable and should not be used near an open flame.
- d. **All of the above are true.**

10. All the following are part of the YCANTH Instructions for Use, except:

- a. Wear gloves and eye protection when administering YCANTH.
- b. **If the YCANTH applicator does not work properly, it is acceptable to modify the tip of the applicator if needed.**
- c. Only apply topically as a single application to cover each lesion.
- d. Administer no more than two YCANTH applicators during a single treatment session, every 3 weeks as needed.
- e. Inspect the YCANTH applicator for damage such as broken glass ampules, cut or cracked tubes. If there is damage, this should be reported within 24 hours to Verrica Pharmaceuticals Inc. at 1-877-837-7422 (1-877-Verrica).